The scaffold of this commentary is oriented to gravitate toward shedding light on the misconception regarding the use of enteric-coated, extended-release or sustained-release forms of nonsteroidal anti-inflammatory drugs (NSAIDs) and the reduction in gastrointestinal (GI) risks. Although evidence is sufficiently available with regard to the inability of these forms to ameliorate GI risks, it has been widely neglected by health care professionals. This dilemma will be approached and elaborated by uncovering historical evidence about the topic of interest followed by theoretical pharmacological explanations.
DaviesNM.Sustained release and enteric coated NSAIDs: are they really GI safe?J Pharm Pharm Sci. 1999;2:5-14.
2.
GoldsteinJLCryerB.Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015;7:31-41.
CryerB.NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality. Am J Gastroenterol. 2005;100:1694-1695.
5.
RainsfordKDBjarnasonI.NSAIDs: take with food or after fasting?J Pharm Pharmacol. 2012;64:465-469.
6.
SostresCGargalloCJArroyoMT. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24:121-132.
7.
LaineL.Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am. 1996;6:489-504.
8.
GriffinMR.Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med. 1998;104:23S-29S; discussion 41S-42S.
9.
ShorrRIRayWADaughertyJR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153:1665-1670.
10.
BruntonLChabnerBKnollmanB.Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 12th ed.New York, NY: McGraw-Hill Education/Medical; 2011.
11.
KatzungBGMastersSBTrevorAJ.Basic and Clinical Pharmacology. 12th ed.London, UK: McGraw-Hill Medical; 2012.
12.
BurianM.NSAIDs, mode of action. In: SchmidtRFWillisWD eds. Encyclopedia of Pain. Berlin, Germany: Springer; 2007:1473-1476.
13.
CashmanDJN. The mechanisms of action of NSAIDs in analgesia. Drugs. 2012;52:13-23.
14.
VaneJRBottingRM.Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104:2S-8S.
15.
VaneJRBottingRM.Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol. 1996;25:9-21.
16.
de AbajoFJGarcía RodríguezLA.Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1:1.
17.
KellyJPKaufmanDWJurgelonJMSheehanJKoffRSShapiroS.Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348:1413-1416.
18.
SheersRWilliamsW.NSAIDs and gut damage. Lancet. 1989;334:1154.
19.
DayTK.Intestinal perforation associated with osmotic slow release indomethacin capsules. Br Med J (Clin Res Ed). 1983;287:1671-1672.
20.
LeufkensHGUrquhartJStrickerBH. Channelling of controlled release formulation of ketoprofen (Oscorel) in patients with history of gastrointestinal problems. J Epidemiol Community Health. 1992;46:428-432.
21.
WhitcombDCMartinSPTrellisDR. “Diaphragmlike” stricture and ulcer of the colon during diclofenac treatment. Arch Intern Med. 1992;152:2341-2343.
